Acute chest syndrome and COVID-19 in sickle cell disease pediatric patients

Elia, Gabriella; Angel, Andrea; Regacini, Rodrigo; Nais, Rafaela Pilotto; Santos, Andréia Regina Augusto dos; Vieira, Pedro Paulo Macarini Gonçalves; Braga, Josefina Aparecida Pellegrini

doi:10.1016/j.htct.2020.11.005

Cited by 11 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… n/a 0 (0) De Luna et al [ 110 ] France 1 (1/0) 45 HbSS BT (1) Severe pneumonia and severe ACS effectively treated with hydroxychloroquine and tocilizumab. n/a 0 (0) Elia et al [ 82 ] Brazil 3 (1/2) 11 HbSS (2), HbSC (1) HU (2) SCD pts. showed better clinical evolution than predicted; Pulmonary viral infections can trigger SCD symptoms and need for hospitalization; COVID-19 symptoms are very similar to ACS symptoms, which affects clinical decision.…”

Section: Patients With Covid-19 and Sickle Cell Diseasementioning

confidence: 99%

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

et al. 2022

View full text Add to dashboard Cite

Section: Patients With Covid-19 and Sickle Cell Diseasementioning

confidence: 99%

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

et al. 2022

View full text Add to dashboard Cite

“…In a case series of seven SCD patients, six with HbSS and one with HbSC, four on HU therapy and one with splenectomy, COVID-19 outcome was favorable. 7 Moreover, in a case series that compared five 18 Finally, as per the international SCD registry, updated April 2, 2021, among 365 SCD patients <19 years with COVID-19, there was one death (0.3%) 9 (Table 1).…”

Section: Childrenmentioning

confidence: 99%

“…Regarding available data, 19 out of 38 pediatric patients were on HU therapy (50%), and in the international SCD registry report, 9 there were 203 out of 365 (55.6%) (Table 1). The mean HbF level was available in three studies 11,15,18 as 17.7%, 12.3%, and 11.3%, respectively.…”

Section: Childrenmentioning

confidence: 99%

Sickle cell disease and COVID‐19: Susceptibility and severity

Sayad

Karimi

Rahimi

2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

We surveyed published papers and an international sickle cell disease (SCD) registry to detect susceptibility and clinical course of coronavirus disease 2019 (COVID‐19) in SCD patients. COVID‐19 presentation was mild in children and moderate in many SCD adults. Regarding increased comorbidities with age, it seems severe COVID‐19 to be more common in older SCD patients. Although the overall outcome of COVID‐19 was favorable in SCD children, a high rate of pediatric intensive care unit admission should be considered in managing these patients. To explain COVID‐19 outcome in SCD patients, the possible benefits of hydroxyurea therapy could be considered. The obtained results should be interpreted, considering low cases from sub‐Saharan people, younger age of SCD patients compared to general population, a bias toward registry of the more severe form of disease, the effect of pre‐existing comorbidities with multisystem organ damage, and the role of health socio‐economic determinants.

show abstract

“…Supporting these case reports, a larger French study found a lower rate of intensive care unit admission for teenagers and young adults with sickle cell and COVID-19 [ 12 ]. ACS in a pediatric patient does not necessarily portend a poor outcome [ 13 , 14 ]. Subsequent data have challenged the notion that sickle cell disease is protective [ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Mortality in a Pediatric Patient with Hemoglobin SC Disease and Alpha-Thalassemia Trait

Motelow

Kahn

Wilson

2021

Case Reports in Critical Care

View full text Add to dashboard Cite

As the pandemic continues to evolve, more cases of COVID-19 in pediatric patients are being detected. A 12-year-old boy with HbSC disease alpha-thalassemia trait presented to a pediatric emergency room with fever and weakness. His vital signs were notable for fever, tachypnea, and tachycardia. His physical exam was concerning for increased work of breathing. He tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by PCR although his hemoglobin level remained near his baseline. His chest radiograph showed a retrocardiac opacity concerning for evolving acute chest syndrome. He decompensated quickly requiring invasive mechanical ventilation and exchange transfusion. He received hydroxychloroquine, broad-spectrum antibiotics, and enoxaparin for DVT prophylaxis. Despite showing clinical signs of improvement, he became acutely hypoxemic and suffered a cardiac arrest. We believe this to be an unusual case of a pediatric patient with HbSC disease and COVID-19. We outline clearly the course of illness and treatments trialed, which can prove beneficial to providers facing similar challenges as this virus continues to strike areas around the world. Although children have significantly better outcomes than adults, providers must remain vigilant while treating any patient with a hemoglobinopathy in the setting of severe COVID-19.

show abstract

Acute chest syndrome and COVID-19 in sickle cell disease pediatric patients

Cited by 11 publications

References 13 publications

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature

Sickle cell disease and COVID‐19: Susceptibility and severity

COVID-19 Mortality in a Pediatric Patient with Hemoglobin SC Disease and Alpha-Thalassemia Trait

Contact Info

Product

Resources

About